Iodide

Iodide

SCHEMBL3815744

C[N+]1(C)C2CCC1CC(CC(c1cccc(Cl)c1)c1cccc(Cl)c1)C2.[I-]

nearest known ligand 0.56

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

ACHECHRM1CHRM3CHRNA1CHRNB1CHRNDCHRNECHRNG

The experimentally established mechanism targets of Iodide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
CHRM3 known ✓ P20309 7/20 0.56
CHRM1 known ✓ P11229 4/20 0.42
PABPC1 P11940 2/20 0.43
CHRM2 P08172 5/20 0.42
BLM P54132 1/20 0.41
SLC6A2 P23975 1/20 0.39
SLC6A4 P31645 1/20 0.39
SLC6A3 Q01959 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.38
OPRM1 P35372 2/20 0.38
OPRD1 P41143 2/20 0.38
OPRK1 P41145 2/20 0.38
OPRL1 P41146 2/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Iodide SCHEMBL5109126 1.00 CHRM3 (0.56) CHRM3PABPC1CHRM2CHRM1BLM
Iodide SCHEMBL5108990 0.97 CHRM3 (0.54) CHRM3PABPC1CHRM2CHRM1BLM
Iodide SCHEMBL3820738 0.97 CHRM3 (0.54) CHRM3PABPC1CHRM2CHRM1BLM
Iodide SCHEMBL5103089 0.83 CHRM3 (0.56) CHRM3PABPC1CHRM2CHRM1
Iodide SCHEMBL5103090 0.83 CHRM3 (0.56) CHRM3PABPC1CHRM2CHRM1
Bromide SCHEMBL5103299 0.81 CHRM3 (0.47) CHRM3PABPC1CHRM2CHRM1BLM
Bromide SCHEMBL3824581 0.81 CHRM3 (0.47) CHRM3PABPC1CHRM2CHRM1BLM
Bromide SCHEMBL5993115 0.81 CHRM3 (0.55) CHRM3PABPC1CHRM2CHRM1BLM
Bromide SCHEMBL5993121 0.81 CHRM3 (0.55) CHRM3PABPC1CHRM2CHRM1BLM
SCHEMBL5096174 0.79 CHRM1 (0.46) CHRM3CHRM2CHRM1SLC6A2SLC6A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1937267-A4 M3 MUSCARINIC ACETYLCHOLINE RECEPTOR ANTAGONISTS GLAXO GROUP LTD (GB) 2009-08-26 EP claimed
US-20080275079-A1 3-Endo)-3-[2,2-Bis-(3-hydroxy-phenyl)-ethenyl]-8,8-dimethyl-8-azonia-bicyclo[3.2.1]octane bromide; chronic obstructive lung disease, chronic bronchitis, asthma, chronic respiratory obstruction, pulmonary fibrosis, pulmonary emphysema, allergic rhinitis GLAXO GROUP LIMITED 2008-11-06 US claimed
EP-1937267-A2 M3 MUSCARINIC ACETYLCHOLINE RECEPTOR ANTAGONISTS GLAXO GROUP LIMITED (GB) 2008-07-02 EP claimed
WO-2007016639-A2 M3 MUSCARINIC ACETYLCHOLINE RECEPTOR ANTAGONISTS GLAXO GROUP LIMITED (GB) 2007-02-08 WO claimed
US-20080275079-A1 3-Endo)-3-[2,2-Bis-(3-hydroxy-phenyl)-ethenyl]-8,8-dimethyl-8-azonia-bicyclo[3.2.1]octane bromide; chronic obstructive lung disease, chronic bronchitis, asthma, chronic respiratory obstruction, pulmonary fibrosis, pulmonary emphysema, allergic rhinitis GLAXO GROUP LIMITED 2008-11-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080275079-A1 3-Endo)-3-[2,2-Bis-(3-hydroxy-phenyl)-ethenyl]-8,8-dimethyl-8-azonia-bicyclo[3.2.1]octane bromide; chronic obstructive lung disease, chronic bronchitis, asthma, chronic respiratory obstruction, pulmonary fibrosis, pulmonary emphysema, allergic rhinitis CHRM3, EDNRB, BDKRB2 CHRM3 1/4885CHRM1 27/4885PABPC1 4445/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.